BackgroundCheck.run
Search For

David L Pompliano, 64119 Westcott Rd, Princeton, NJ 08540

Known as:
Dave L Pompliano David O
Related to:
Lillian E Keys

David Pompliano Phones & Addresses

119 Westcott Rd, Princeton, NJ 08540    609-6831233   

Telford, PA   

Bradley Beach, NJ   

Kitty Hawk, NC   

Trenton, NJ   

Lansdale, PA   

Wilmington, DE   

Montgomery, PA   

Princeton Junction, NJ   

Statesville, NC   

Get Report
Control this profile

Mentions for David L Pompliano

David Pompliano resumes & CV records

Resumes

David Pompliano Photo 14

Principal And Owner

Location:
Princeton, NJ
Industry:
Pharmaceuticals
Work:
Lodo Therapeutics Corporation Sep 2018 - Aug 2019
Senior Scientific Advisor Lodo Therapeutics Corporation Sep 2015 - Sep 2018
Co-Founder and Chief Scientific Officer Rockefeller University Sep 2015 - Sep 2018
Visiting Scientist, Brady Lab Revolution Medicines Jun 2015 - Aug 2017
Advisor Accelerator Life Science Partners Jun 2015 - Aug 2017
Operating Partner Revolution Medicines Dec 2014 - May 2015
Co-Founder and Chief Scientific Officer Third Rock Ventures Oct 2013 - Nov 2014
Entrepreneur In Residence Bioleap Feb 2009 - Nov 2012
President and Chief Executive Officer Sanderling Consulting Feb 2009 - Nov 2012
Principal and Owner Merck May 2007 - Nov 2008
Vice President, Vaccines and Infectious Diseases Franchise Gsk Feb 2002 - May 2007
Vice President, Head of Biology For Mmpd and Id Cedds Dupont Pharmaceuticals Apr 1999 - Dec 2001
Executive Director, Antimicrobial and Angiogenesis Discovery Merck Aug 1990 - Apr 1999
Director, Biochemistry
Education:
Harvard University 1988 - 1990
Stanford University 1982 - 1987
Doctorates, Doctor of Philosophy, Chemistry University of Virginia 1978 - 1982
Bachelors, Bachelor of Science, Chemistry
Skills:
Drug Discovery, Drug Development, Biotechnology, Pharmaceutical Industry, Infectious Diseases, Biochemistry, Oncology, Life Sciences, Biopharmaceuticals, Clinical Development, Strategy, Lifesciences, Technology Transfer, Pharmaceutics, Protein Chemistry, Clinical Trials, Molecular Biology, R&D, Commercialization, Medicinal Chemistry, Vaccines, Immunology, Regulatory Affairs, Clinical Research, Microbiology, Chemistry, Fda, Cell Biology, Organic Chemistry, Cell, Pharmacology, Biomarkers, Cro, Diabetes, Research and Development
Languages:
English
David Pompliano Photo 15

David Pompliano

Publications & IP owners

Us Patents

Fluorescence Assay Of Ras Farnesyl Protein Transferase

US Patent:
5525479, Jun 11, 1996
Filed:
Feb 17, 1994
Appl. No.:
8/199778
Inventors:
Neville J. Anthony - Hatfield PA
David L. Pompliano - Lansdale PA
Assignee:
Merck & Co., Inc. - Rahway NJ
International Classification:
C12Q 148
C12Q 100
A01N 3718
US Classification:
435 15
Abstract:
This invention is directed to a continuous fluorescence assay of Ras farnesyl:protein transferase. This assay can be used to screen for inhibitors of farnesyl:protein transferase. The assay may also be modified to screen for inhibitors of other protein transferases.

Metabolic Pathway Assay

US Patent:
5891621, Apr 6, 1999
Filed:
Sep 24, 1997
Appl. No.:
8/936646
Inventors:
Renee M. Chabin - Neptune NJ
David W. Kuo - Princeton NJ
John F. O'Connell - Cranbury NJ
David L. Pompliano - Lawrenceville NJ
Kenny K. Wong - Edison NJ
Assignee:
Merck & Co., Inc. - Rahway NJ
International Classification:
C12Q 100
C12Q 137
C12Q 118
C12Q 148
US Classification:
435 4
Abstract:
An in vitro screening assay which identifies enzyme inhibitors and allows for the simultaneous assay of many enzymes. Enzyme, substrate, co-factor, etc. concentrations are optimized so that inhibitors of any one of the enzymes in the pathway are equally likely to be detected. Necessarily, the flux of substrate through each enzyme should be nearly the same during the assay, i. e. , each of the enzyme catalyzed steps must be equally rate-limiting. Preferably, optimal assay conditions are predicted by computer modeling. Further, the pathway conditions are optimized through variation of enzyme, starting substrate, co-substrate and co-factor concentrations. A positive response is initially detected as a change in the amount of the product generated at the end of the enzyme cascade as compared to a standard. A sample producing a positive result can be deconvoluted.

Expression And Purification Of Phosphoinositide-Specific Phospholipase C-.Gamma.

US Patent:
5474921, Dec 12, 1995
Filed:
Oct 15, 1993
Appl. No.:
8/138641
Inventors:
Kenneth S. Koblan - Chalfont PA
David L. Pompliano - Lansdale PA
Assignee:
Merck & Co., Inc. - Rahway NJ
International Classification:
C12N 916
C12N 920
C12N 1555
C07K 122
US Classification:
435196
Abstract:
The present invention is directed to an assay which is used to determine the inhibitory activity of a test compound against a particular phosphoinositide-specific phospholipase C enzyme, that enzyme being phospholipase C. gamma. The present invention is also directed to the preparation of phospholipase C. gamma. by recombinant expression in a bacterial cell and isolation of the expressed enzyme.

Possible Relatives

Dolores M Pompliano  Richard J Pompliano  Robert J Pompliano  Anthony J Pompliano  David Last  David W Johnson  David Stamps  David L Stanard  David M Stanbery  David A Stanchfield 

NOTICE: You may not use BackgroundCheck or the information it provides to make decisions about employment, credit, housing or any other purpose that would require Fair Credit Reporting Act (FCRA) compliance. BackgroundCheck is not a Consumer Reporting Agency (CRA) as defined by the FCRA and does not provide consumer reports.